Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome

Thrombosis Research

Volumn 124, Issue 1, 2009, Pages 6-13

  Dupont, Allison G ^a   Gabriel, Don A ^a   Cohen, Mauricio G ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; Antiplatelet drugs; Antiplatelet resistance

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; CYCLOOXYGENASE 1 INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; IBUPROFEN; NAPROXEN; PRASUGREL; RAPAMYCIN; SULFINPYRAZOLE; SULOTROBAN; TACROLIMUS; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL; DRUG BINDING; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG MECHANISM; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; LOW DRUG DOSE; NEUTROPENIA; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS AS TOPIC; CORONARY ANGIOGRAPHY; DRUG RESISTANCE; HUMANS; MODELS, BIOLOGICAL; PLATELET AGGREGATION INHIBITORS;

EID: 64749086877     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.01.014     Document Type: Review

References (69)

1. Stein B., Badimon L., Israel D.H., Badimon J.J., and Fuster V. Thrombosis/platelets and other blood factors in acute coronary syndromes. Cardiovasc Clin 20 1 (1989) 105-129
2. Freedman J.E., and Loscalzo J. Nitric oxide and its relationship to thrombotic disorders. J Thromb Haemost 1 6 (2003) 1183-1188
3. Ruggeri Z.M., and Mendolicchio G.L. Adhesion mechanisms in platelet function. Circ Res 100 12 (2007) 1673-1685
4. Meadows T.A., and Bhatt D.L. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 100 9 (2007) 1261-1275
5. Konkle B.A., and S.A. Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease, in Braunwald's Heart Disease: A textbook of cardiovascular medicine. In: Braunwald E. (Ed) (2005), Elsevier Saunders, Philadelphia 2067-2092
6. Mehta S.R., and Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 41 4 Suppl S (2003) 79S-88S
7. Weiss H.J., and Aledort L.M. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 2 7514 (1967) 495-497
8. Lewis Jr. H.D., Davis J.W., Archibald D.G., Steinke W.E., Smitherman T.C., Doherty III J.E., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309 7 (1983) 396-403
9. Cairns J.A., Gent M., Singer J., Finnie K.J., Froggatt G.M., Holder D.A., et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 313 22 (1985) 1369-1375
10. Theroux P., Ouimet H., McCans J., Latour J.G., Joly P., Levy G., et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319 17 (1988) 1105-1111
11. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 336 8719 (1990) 827-830
12. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj 324 7329 (2002) 71-86
13. Savage M.P., Goldberg S., Bove A.A., Deutsch E., Vetrovec G., Macdonald R.G., et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 92 11 (1995) 3194-3200
14. Peters R.J., Mehta S.R., Fox K.A., Zhao F., Lewis B.S., Kopecky S., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108 14 (2003) 1682-1687
15. Mehta S.R. Clopidogrel in non-ST-segment elevation acute coronary syndromes. Eur Heart J Suppl 8 (2006) G25-G30 (Supplement G), 2006
16. Storey R.F., Sanderson H.M., White A.E., May J.A., Cameron K.E., and Heptinstall S. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 110 4 (2000) 925-934
17. Rehmel J.L., Eckstein J.A., Farid N.A., Heim J.B., Kasper S.C., Kurihara A., et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34 4 (2006) 600-607
18. Hall P., Nakamura S., Maiello L., Itoh A., Blengino S., Martini G., et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 93 2 (1996) 215-222
19. Schomig A., Neumann F.J., Kastrati A., Schuhlen H., Blasini R., Hadamitzky M., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 17 (1996) 1084-1089
20. Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 23 (1998) 1665-1671
21. Bertrand M.E., Legrand V., Boland J., Fleck E., Bonnier J., Emmanuelson H., et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 98 16 (1998) 1597-1603
22. Urban P., Macaya C., Rupprecht H.J., Kiemeneij F., Emanuelsson H., Fontanelli A., et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98 20 (1998) 2126-2132
23. Bennett J.S. Novel platelet inhibitors. Annu Rev Med 52 (2001) 161-184
24. Urban P., Macaya C., Rupprecht H.J., Kiemeneij F., Emanuelsson H., Fontanelli A., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110 10 (2004) 1202-1208
25. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 9281 (2001) 527-533
26. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Jama 288 19 (2002) 2411-2420
27. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey Jr. D.E., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50 7 (2007) e1-e157
28. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 20 (2007) 2001-2015
29. Plow E.F., and Ginsberg M.H. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 9 (1989) 117-156
30. Steinhubl S.R. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study. J Thromb Thrombolysis 9 3 (2000) 199-205
31. Chew D.P., Bhatt D.L., Sapp S., and Topol E.J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103 2 (2001) 201-206
32. Kong D.F., Califf R.M., Miller D.P., Moliterno D.J., White H.D., Harrington R.A., et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98 25 (1998) 2829-2835
33. Lincoff A.M., Califf R.M., Anderson K.M., Weisman H.F., Aguirre F.V., Kleiman N.S., et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators.Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 30 1 (1997) 149-156
34. Bellandi F., Maioli M., Leoncini M., Toso A., and Dabizzi R.P. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. Int J Cardiol 108 1 (2006) 36-42
35. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352 9122 (1998) 87-92
36. Topol E.J., Mark D.B., Lincoff A.M., Cohen E., Burton J., Kleiman N., et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 354 9195 (1999) 2019-2024
37. Kandzari D.E., Hasselblad V., Tcheng J.E., Stone G.W., Califf R.M., Kastrati A., et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 147 3 (2004) 457-462
38. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 338 21 (1998) 1498-1505
39. Alexander J.H., and Harrington R.A. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Drugs 56 6 (1998) 965-976
40. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 338 21 (1998) 1488-1497
41. Schneider D.J., Herrmann H.C., Lakkis N., Aguirre F., Wan Y., Aggarwal A., et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 90 12 (2002) 1421-1423
42. McBane R.D., Wysokinski M.D., Waldemar E., and M.D. Treatment and Prevention of Arterial Thrombosis. In: Joseph M., and Murphy G. (Eds). Mayo Clinic Cardiology: Concise Textbook (2007), Mayo Clinic Scientific Press, Rochester 635-654
43. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339 7 (1998) 436-443
44. Gilchrist I.C., O'Shea J.C., Kosoglou T., Jennings L.K., Lorenz T.J., Kitt M.M., et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 104 4 (2001) 406-411
45. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 349 9063 (1997) 1422-1428
46. Gurbel P.A., Bliden K.P., Zaman K.A., Yoho J.A., Hayes K.M., and Tantry U.S. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111 9 (2005) 1153-1159
47. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 336 24 (1997) 1689-1696
48. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 96 5 (1997) 1445-1453
49. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356 9247 (2000) 2037-2044
50. Montalescot G., Barragan P., Wittenberg O., Ecollan P., Elhadad S., Villain P., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 25 (2001) 1895-1903
51. Simoons M.L. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357 9272 (2001) 1915-1924
52. Krasopoulos G., Brister S.J., Beattie W.S., and Buchanan M.R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. Bmj 336 7637 (2008) 195-198
53. Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., and Michelson A.D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50 19 (2007) 1822-1834
54. Nappi J. Benefits and limitations of current antiplatelet therapies. Am J Health Syst Pharm 65 13 Suppl 5 (2008) S5-S10 quiz S16-8.
55. Goodman S.G., Fitchett D., Armstrong P.W., Tan M., and Langer A. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 107 2 (2003) 238-244
56. Lancaster G.I., Jain H., and Zarich S.W. The role of aspirin resistance in the treatment of acute coronary syndromes. Clin Cardiol 31 1 (2008) 11-17
57. Lea Bonello. Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicentre Randomized Prospective Study in Presented by Dr. Laurent Bonello at the SCAI-ACC i2 Summit/American College of Cardiology Annual Scientific Session, Chicago, IL, March/April 2008. 2008.
58. Nguyen T.A., Diodati J.G., and Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45 8 (2005) 1157-1164
59. Michelson A.D., Cattaneo M., Eikelboom J.W., Gurbel P., Kottke-Marchant K., Kunicki T.J., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 6 (2005) 1309-1311
60. Shantsila E., Watson T., and Lip G.Y. Aspirin resistance: what, why and when?. Thromb Res 119 5 (2007) 551-554
61. Gasparyan A.Y., Watson T., and Lip G.Y. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 51 19 (2008) 1829-1843
62. Pusch G., Feher G., Kotai K., Tibold A., Gasztonyi B., Feher A., et al. Aspirin resistance: focus on clinical endpoints. J Cardiovasc Pharmacol 52 6 (2008) 475-484
63. Shantsila E., and Lip G.Y. 'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications?. J Transl Med 6 (2008) 47
64. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 25 (2001) 1809-1817
65. Szczeklik A., Musial J., Undas A., and Sanak M. Aspirin resistance. J Thromb Haemost 3 8 (2005) 1655-1662
66. Martorell L., Martinez-Gonzalez J., Rodriguez C., Gentile M., Calvayrac O., and Badimon L. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost 99 2 (2008) 305-315
67. Leger A.J., Jacques S.L., Badar J., Kaneider N.C., Derian C.K., Andrade-Gordon P., et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113 9 (2006) 1244-1254
68. Fugate S.E., and Cudd L.A. Cangrelor for treatment of coronary thrombosis. Ann Pharmacother 40 5 (2006) 925-930
69. Husted S. New developments in oral antiplatelet therapy. Eur Heart J Suppl 9 (2007) D20-D27 (Supplement D), 2007